Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Among authors: masuda n. Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9. Lancet. 2020. PMID: 33278935 Clinical Trial.
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S, Mukai H, Iwata H, Watanabe T, Shimizu C, Nakagami K, Tamura M, Ito T, Masuda N, Ogino N, Hisamatsu K, Mitsuyama S, Abe H, Tanaka S, Yamaguchi T, Ohashi Y. Aihara T, et al. Among authors: masuda n. Breast Cancer Res Treat. 2010 Jun;121(2):379-87. doi: 10.1007/s10549-010-0888-x. Breast Cancer Res Treat. 2010. PMID: 20390343 Clinical Trial.
Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)].
Taguchi T, Masuda N, Nakayama T, Motomura K, Tsukamoto F, Shimazu K, Nomura T, Morimoto T, Yamamoto H, Wakita K, Nakano Y, Yoneda K, Inaji H, Takatsuka Y, Noguchi S; Kinki Breast Cancer Study Group (KBCSG). Taguchi T, et al. Among authors: masuda n. Oncology. 2010;78(5-6):302-8. doi: 10.1159/000318169. Epub 2010 Jul 2. Oncology. 2010. PMID: 20606491 Clinical Trial.
First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K, Masuda N, Ohno S, Oda T, Iwata H, Kashiwaba M, Fujiwara Y, Kamigaki S, Ito Y, Ueno T, Takashima S. Aogi K, et al. Among authors: masuda n. Breast Cancer Res Treat. 2011 Oct;129(3):829-38. doi: 10.1007/s10549-011-1685-x. Epub 2011 Jul 31. Breast Cancer Res Treat. 2011. PMID: 21805309 Clinical Trial.
A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.
Shien T, Nakamura K, Shibata T, Kinoshita T, Aogi K, Fujisawa T, Masuda N, Inoue K, Fukuda H, Iwata H. Shien T, et al. Among authors: masuda n. Jpn J Clin Oncol. 2012 Oct;42(10):970-3. doi: 10.1093/jjco/hys120. Epub 2012 Jul 24. Jpn J Clin Oncol. 2012. PMID: 22833684 Clinical Trial.
1,172 results